Weight Loss Multiple Incretin Agonists Clinical use

Mazdutida

Also known as: IBI362, LY3305677, Mazdutide

Mazdutide is a dual GLP-1 and glucagon receptor agonist derived from oxyntomodulin. It combines the appetite reduction and glycemic improvement of GLP-1 with the glucagon-driven increase in energy expenditure, positioning it as a next-generation metabolic therapy for obesity and type 2 diabetes.

Mechanism of action

Mazdutide simultaneously activates two complementary receptors.

GLP-1 receptor: increases glucose-dependent insulin secretion, reduces postprandial glucagon, delays gastric emptying and decreases appetite.
Glucagon receptor: raises energy expenditure and hepatic lipolysis, favoring fat loss.
Result: greater weight loss and possible benefit on fatty liver.

Uses & indications

Obesity and overweight.
Type 2 diabetes mellitus.
Metabolic liver disease (MASLD/MASH): under research.

Effects

Intended effects: significant weight loss, improved glycemic control and hepatic lipids.

Adverse effects: similar to incretins: nausea, diarrhea, vomiting and constipation, usually transient. Due to the glucagon component, monitor blood pressure and heart rate.

Considerations & contraindications

Recent drug; long-term experience still limited outside trials.
Same precautions as GLP-1 (medullary thyroid, pancreatitis).
The glucagon component may raise hepatic glucose: careful adjustment in diabetics.

Regulatory approval

Approved in China (NMPA, 2025) for obesity; in advanced clinical development for other indications. No FDA/EMA approval at the time of writing.

Dosage

Weekly subcutaneous doses with progressive titration have been evaluated in trials. This is not a clinical recommendation.

Storage

Lyophilized: 2–8 °C. Reconstituted: refrigerate (2–8 °C), protect from light and use within a few weeks.

Technical data

Regulatory status Clinical use

Molecular weight ~4800 Da (aprox.)

Half-life ~Varios días (administración semanal)

Administration routes Subcutánea